PDCD1 and hepatocellular carcinoma: Our study is the first to evaluate the efficacy of HAIC plus TKI and PD-1 inhibitors in high-risk aHCC with a large sample size, and we also compared it with the first-line treatment recommended by the HCC guidelines.